Amphastar Pharmaceuticals, Inc. 8-K

What Happened
Amphastar Pharmaceuticals, Inc. (AMPH) announced its financial results for the three months and fiscal year ended December 31, 2025 via a press release dated February 26, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8‑K (Item 2.02). The filing states the furnished information is not “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Date of announcement: February 26, 2026.
• Period covered: three months and fiscal year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K signed by William J. Peters, Chief Financial Officer, Executive Vice President and Treasurer.

Why It Matters
This 8‑K signals Amphastar has published its quarterly and full‑year earnings information; investors should review the press release (Exhibit 99.1) for revenue, net income (or loss), EPS, segment results, and any commentary on guidance or material events. Because the release is “furnished” rather than “filed,” it carries different disclosure and liability implications under the securities laws. Check the exhibit and any subsequent filings (e.g., Form 10‑K or earnings call materials) for complete financial details and management commentary.